Company Filing History:
Years Active: 2023
Title: Sylvie Guichard: Innovator in Cancer Treatment
Introduction
Sylvie Guichard is a prominent inventor based in Watertown, MA (US). She has made significant contributions to the field of cancer treatment, particularly in developing methods for treating androgen receptor-driven cancers. Her innovative work has the potential to impact the lives of many patients suffering from these conditions.
Latest Patents
Sylvie Guichard holds a patent for "Bromodomain inhibitors for androgen receptor-driven cancers." This patent discloses methods for treating certain androgen receptor-positive forms of cancer using inhibitors of the CREB binding protein bromodomain. The patent specifically addresses treatments for breast cancer, including triple-negative forms, hormone receptor-positive forms, and HER2-positive forms. Additionally, it covers methods for treating prostate cancer, including metastatic castration-resistant prostate cancer. One of the key compounds mentioned in her patent is (1R,3R)-3-[(7S)-2-[(R)-(5-fluoro-2-methoxyphenyl)(hydroxy)methyl]-6-(methoxycarbonyl)-7-methyl-3H,6H,7H,8H,9H-imidazo[4,5-f]quinolin-3-yl]cyclohexane-1-carboxylic acid, or a pharmaceutically acceptable salt thereof.
Career Highlights
Sylvie Guichard is currently associated with Forma Therapeutics, Inc., where she continues her research and development efforts. Her work is focused on advancing therapeutic options for patients with challenging cancer diagnoses. With her expertise, she has positioned herself as a key figure in the fight against cancer.
Collaborations
Sylvie collaborates with talented professionals in her field, including Maureen Caligiuri and Anna M Ericsson. These collaborations enhance her research and contribute to the development of innovative cancer treatments.
Conclusion
Sylvie Guichard's contributions to cancer treatment through her innovative patents and collaborations highlight her dedication to improving patient outcomes. Her work exemplifies the impact that inventors can have in the medical field.